2024-2025 COVID-19 PFIZER Vaccination Consent for 12yo through Adults

		GIACIAL RIDGE HEALTH SYSTEM			
Last name:		First Name:	Middle Initial:		
Home Zip Co	ode:	Date of birth:	Age:		
COVID-19 vaccination	1.	Are you sick today? (minor illness is not a contraindication to vacci	nation)	□ Yes	□No
screening questions:	2.	Do you have a life-threatening allergy to any vaccine or any vaccine NOT VACCINATE. Speak with your provider.	e components? If yes, DO	☐ Yes	□No
	3.	Are you pregnant or breastfeeding? (Discussion of risks and benefit recommended prior to vaccination. This is not a contraindication.)	ts with your PCP is	☐ Yes	□No
	4.	Are you immunosuppressed due to health condition or treatment?	(mark on reverse)	□ Yes	□No
	5.	I am unvaccinated against COVID OR have not received the updated 2024 been at least 2 months since I received any COVID vaccineGive 2024-20		□ Yes	□No
	6.	I am 65 years old or older and I am moderately to severely immunocomp least 2 months since I received the 2024-2025 COVID vaccine —Giv COVID vaccine		☐ Yes	□No
INFORMED	СО	NSENT:			
I, (print nam vaccination.		, hereby ackr	owledge and assume the r	isk of CO	VID-19
		OVID-19 Pfizer 2024-2025 Vaccination has received FDA Authorization for pree opportunity to review the patient fact sheet for this vaccine.	evention of COVID-19 in persons	12 years ol	d or
		at there is limited information known about the safety and eff xpected side effects may occur. Known possible side effects in	•	vaccine.	
face Imn Pair Swo Syno Ver	e, or nune n/sw ollen cope y rar	reactions: low blood pressure, changes in heartbeat, shortness throat, rash, nausea, vomiting, sweating, or shivering, possible system reaction: fever, chills, muscle/joint pain, headache, falling/redness at injection site lymph nodes, particularly after a booster dose (fainting) may occur with administration of injectable vaccine ly: inflammation of the heart muscle or the tissues surround g vaccination. The observed risk is highest in males 12-17 year	e during or after infusion atigue es, especially among adolesing the heart particularly in	cents.	
l un this time, in opportunity YES, I con the vaccir	ders add to r sen	itand the COVID-19 vaccine may cause additional risks, some of ition to the risks described above, as well as those risks for the review the fact sheet on this medication. (Continue to reverse at to have the COVID-19 vaccine given to me/ my child oes not preclude me/my child from wearing a mask whomply with Minnesota Department of Health regulation	of which may not currently the treatment itself. I have hat itself. I have hat it itself. I have hat it itself. I understand the commended and I itself.	nd an at receiv	ving
 Pati	ent/	Representative Signature & Relationship to patient	 Date	_	
		mirnaty 12 AND OLDER 0.3ML			
		d/info given:/	Date of vaccine info sheet: 10/	19/2023	

Date administered/info given:/	Date of vaccine info sheet: 10/19/2023	
Lot #:LM2219 EXP 3/29/2025LM2215 EXP 3/15/2025LM2221 EXP 1/4/2025	Mfg: Pfizer COVID-19	CPT Code:
Route/Dose: 0.3ml IM (12 +)	IM Site: R delt L delt	Name and title of vaccine administrator:

2024-2025 COVID-19 PFIZER Vaccination Consent for 12yo through Adults



ELIGIBILITY FOR IMMUNOCOMPROMISED DOSE OF COVID PFIZER VACCINE					
Currently receiving treatment for cancer					
Have had an organ transplant and are on immunosuppression therapy					
Have had a blood stem cell transplant or CAR-T cell transplant AND					
are within 2 years of transplant or					
are on immunosuppression therapy					
Currently being treated with immunosuppressive medications such as					
high dose corticosteroids (>20 mg prednisone or equivalent/day)					
alkylating agents, antimetabolites, TNF blockers, severely immunosuppressive cancer chemotherapeutic agents, transplant related immunosuppressive drugs					
other biologic agents that are immunosuppressive or immunododulatory*					
Have advanced or untreated HIV infection					

Verify the single dose glass prefilled syringes (including labels) prior to preparation for administration to help avoid vaccine administration errors

Have a moderate or severe PRIMARY immunodeficiency (e.g. DiGeorge syndrome, Wiskott-Aldrich syndrome)

	2024-2025 Formula of COMIRNATY SINGLE DOSE GLASS PREFILLED SYRINGE DO NOT FREEZE	
Age group	12 years and older	
Verify syringe label states "2024-2025 Formula" Confirm NDC	COVID-19 Vaccini COMIRNATY 2024-2025 formula DO NOT FREEZ Age 12/ & Older **casson of A.3 rest.**	
Dose	30 mcg	
Dose volume	0.3 mL	
	Storage Conditions*1	
Room temperature [8°C to 25°C (46°F to 77°F)]	Must not exceed 12 hours*	
Refrigerator [2°C to 8°C (35°F to 46°F)]	Refrigerator-stable for up to 8 months from date of manufacture to the expiration date printed on the carton and on the syringe labels	
Freezer [-25°C to -15°C (-13°F to 5°F)]	DO NOT STORE	
Ultra-Low-Temperature (ULT) freezer [-90°C to -60°C (-130°F to -76°F)]	DO NOT STORE	

^{*}Regardless of storage condition, the vaccine should not be used after the expiration date printed on the glass prefilled syringes and cartons.

*Regardless of presentation, during storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

*Do not shake. Remove tip cap by slowly turning the cap counterclockwise while holding the Luer lock and attach a sterile needle. Use immediately. If COMIRNATY cannot be used immediately, it must be used within 4 hours.

Important Reminder

Previous COVID-19 vaccines are no longer available for use in the United States.

FDA and CDC guidance is to check inventory and dispose of previous COVID-19 vaccines according to state and local regulations.

Confirm syringe label states "2024-2025 Formula"

GLASS PREFILLED SYRINGES

DO NOT FREEZE. If glass prefilled syringes have been frozen, discard.